If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-10. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
In the African-American slave community, slaves quickly adopted funeral procedures and the location of gravesites of family and friends. Specific slaves were assigned to prepare dead bodies, build coffins, dig graves, and construct headstones. Slave funerals were typically at night when the workday was over, with the master present to view all the ceremonial procedures. Slaves from nearby plantations were regularly in attendance. At death, a slave's body was wrapped in cloth. The hands were placed across the chest, and a metal plate was placed on top of their hands. The reasoning for the plate was to hinder their return home by suppressing any spirits in the coffin. Often, personal property was buried with slaves to appease spirits. The coffins were nailed shut once the body was inside, and carried by hand or wagon, depending on the property designated for the slave burial site. Slaves were buried oriented east to west, with feet at the eastern end and head at the western end and the person thus rising facing east. According to Christian doctrine, this orientation permitted rising to face the return of Christ without having to turn around upon the call of Gabriel's trumpet. Gabriel's trumpet would be blown near the eastern sunrise.
== History == Dutasteride was patented in 1996 and was first described in the scientific literature in 1997. It was approved by the FDA for the treatment of BPH in November 2001, and was introduced on the United States market the following year under the brand name Avodart. Dutasteride has subsequently been introduced throughout the world. The patent protection of dutasteride expired in November 2015, so the drug has since become available in the United States in a variety of low-cost generic formulations. It was approved for the treatment of scalp hair loss in South Korea in 2009, in Japan in 2015 and in Taiwan in 2016. It has not been approved for this indication in the United States, though it is often used off-label both orally and topically.
=== November 2005 === -173 detainees found in an Iraqi government bunker in Baghdad were found starved, beaten and tortured. -Colin Powell's former Chief of Staff, Colonel Lawrence Wilkerson, stated in an interview with Amy Goodman on November 22 that:
== Evolution == Aquatic plants have adapted to live in either freshwater or saltwater. Aquatic vascular plants have originated on multiple occasions in different plant families; they can be ferns or angiosperms (including both monocots and dicots). The only angiosperms capable of growing completely submerged in seawater are the seagrasses. Examples are found in genera such as Thalassia and Zostera. An aquatic origin of angiosperms is supported by the evidence that several of the earliest known fossil angiosperms were aquatic. Aquatic plants are phylogenetically well dispersed across the angiosperms, with at least 50 independent origins, although they comprise less than 2% of the angiosperm species. Archaefructus represents one of the oldest, most complete angiosperm fossils which is around 125 million years old. These plants require special adaptations for living submerged in water or floating at the surface.
Sources: en.wikipedia.org
Fimbrian legions: 86 BC – 66 BC, Lucius Valerius Flaccus. These two legions fought in the Mithridatic Wars. Legio I Germanica (Germanic): 48 BC – AD 70 (Revolt of the Batavi), Julius Caesar (emblem: bull) Legio II Sabina (Sabine): 43 BC – 4th century AD, early name of the Legio II Augusta, Octavian Legio III Cyrenaica (from Cyrene): probably c. 36 BC to (at least) the 5th century, Mark Antony Legio III Gallica (Gallic): around 49 BC to at least early 4th century, Julius Caesar (emblem: bull) Legio IV Macedonica (Macedonian): 48 BC – AD 70 (renamed by Vespasian), Julius Caesar (emblem: bull, capricorn) Legio IV Scythica (from Scythia): c.
S. haemolyticus can colonize central venous catheters and cause serious medical complications. Colonization occurs when S. haemolyticus migrates from the skin, along the external surface of the device, or from the hub, due to manipulation by health care workers. In either scenario, a high probability exists that the microbe will form a biofilm. These infections can remain localized or become systemic (i.e. bacteremia). The severity of infection varies depending on the type of catheter, frequency of manipulation, and virulence factors of the S. haemolyticus strain. Removal of the catheter is usually considered to be the best treatment, but this is not always possible. Alternatively, vancomycin or teicoplanin may be administered. Recent evidence suggests that glycopeptides can be supplemented with β-lactams to work synergistically.
=== Introns can be mobile genetic elements === Some self-splicing introns can spread through a population of organisms by "homing", inserting copies of themselves into genes at sites that previously lacked an intron. Because they are self-splicing (that is, they remove themselves at the RNA level from genes into which they have inserted), these sequences represent transposons that are genetically silent, i.e. they do not interfere with the expression of the gene into which they become inserted. These introns can be regarded as examples of selfish DNA. Some mobile introns encode homing endonucleases, enzymes that initiate the homing process by specifically cleaving double-stranded DNA at or near the intron-insertion site of alleles lacking an intron. Mobile introns are frequently members of either the group I or group II families of self-splicing introns.
Sources: en.wikipedia.org
Deionized water is very often used as an ingredient in many cosmetics and pharmaceuticals. "Aqua" is the standard name for water in the International Nomenclature of Cosmetic Ingredients standard, which is mandatory on product labels in some countries. Because of its high relative dielectric constant (~80), deionized water is also used (for short durations, when the resistive losses are acceptable) as a high voltage dielectric in many pulsed power applications, such as the Sandia National Laboratories Z Machine. Distilled water can be used in PC water-cooling systems and Laser Marking Systems. The lack of impurity in the water means that the system stays clean and prevents a buildup of bacteria and algae. Also, the low conductance reduces the risk of electrical damage in the event of a leak. However, deionized water has been known to cause cracks in brass and copper fittings. When used as a rinse after washing cars, windows, and similar applications, purified water dries without leaving spots caused by dissolved solutes. Deionized water is used in water-fog fire-extinguishing systems used in sensitive environments, such as where high-voltage electrical and sensitive electronic equipment is used. The 'sprinkler' nozzles use much finer spray jets than other systems and operate at up 35 MPa (350 bar; 5,000 psi) of pressure. The extremely fine mist produced takes the heat out of fire rapidly, and the fine droplets of water are nonconducting (when deionized) and are less likely to damage sensitive equipment.
To identify the more likely molecular formulas for an unknown compound based on the matching between the observed isotope abundance pattern in an experiment and the expected isotope abundance patterns for given molecular formulas. To expand the linear dynamic response range of the mass spectrometer by following multiple isotopologues, with an isotopologue of lower abundance still generating linear response even while the isotopologues of higher abundance giving saturated signals.
== Interactions == Fremanezumab does not interact with other antimigraine drugs such as triptans, ergot alkaloids and analgesics. It is expected to generally have a low potential for interactions, because it is not metabolized by cytochrome P450 enzymes.
=== Sexuality === Recent studies found that eating disorders, with the inclusion of BED, are found to be prominent in LGBTQ groups due to higher rates of depression when compared to the general population. This could be due to the stress and discrimination this population experiences. Furthermore, adolescent and young adult sexual minority males binge at higher rates than their heterosexual counterparts.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.